Your browser doesn't support javascript.
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.
Millat-Martinez, Pere; Gharbharan, Arvind; Alemany, Andrea; Rokx, Casper; Geurtsvankessel, Corine; Papageourgiou, Grigorios; van Geloven, Nan; Jordans, Carlijn; Groeneveld, Geert; Swaneveld, Francis; van der Schoot, Ellen; Corbacho-Monné, Marc; Ouchi, Dan; Piccolo Ferreira, Francini; Malchair, Pierre; Videla, Sebastian; García García, Vanesa; Ruiz-Comellas, Anna; Ramírez-Morros, Anna; Rodriguez Codina, Joana; Amado Simon, Rosa; Grifols, Joan-Ramon; Blanco, Julian; Blanco, Ignacio; Ara, Jordi; Bassat, Quique; Clotet, Bonaventura; Baro, Bàrbara; Troxel, Andrea; Zwaginga, Jaap Jan; Mitjà, Oriol; Rijnders, Bart J A.
  • Millat-Martinez P; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Gharbharan A; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Alemany A; Department of Internal Medicine, Section of Infectious Diseases and department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
  • Rokx C; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Geurtsvankessel C; Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Papageourgiou G; Facultat de Medicina-Universitat de Barcelona, Barcelona, Spain.
  • van Geloven N; Department of Internal Medicine, Section of Infectious Diseases and department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
  • Jordans C; Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
  • Groeneveld G; Department of Biostatistics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
  • Swaneveld F; Department of Biomedical Data Sciences, Section of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands.
  • van der Schoot E; Department of Internal Medicine, Section of Infectious Diseases and department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
  • Corbacho-Monné M; Department of Infectious Diseases and Acute Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  • Ouchi D; Unit of Transfusion Medicine, Sanquin Blood Supply, Amsterdam, The Netherlands.
  • Piccolo Ferreira F; Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.
  • Malchair P; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Videla S; Facultat de Medicina-Universitat de Barcelona, Barcelona, Spain.
  • García García V; Hospital Universitari Parc Taulí I3PT, Sabadell, Spain.
  • Ruiz-Comellas A; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Ramírez-Morros A; Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Rodriguez Codina J; Bioclever-CRO, Barcelona, Spain.
  • Amado Simon R; Emergency Department, Bellvitge University Hospital, L'Hospitalet de LLobregat, Barcelona, Spain.
  • Grifols JR; Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.
  • Blanco J; Clinical Research Support Unit (HUB-IDIBELL: Bellvitge University Hospital & Bellvitge Biomedical Research Institute), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Blanco I; Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and 33 Health Sciences, IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Ara J; Emergency Department, Bellvitge University Hospital, L'Hospitalet de LLobregat, Barcelona, Spain.
  • Bassat Q; Unitat de Suport a la Recerca de la Catalunya Central, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Sant Fruitós de Bages, Spain.
  • Clotet B; Health Promotion in Rural Areas Research Group, Gerència Territorial de la Catalunya Central, Institut Català de la Salut, Sant Fruitós de Bages, Spain.
  • Baro B; Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain.
  • Troxel A; Unitat de Suport a la Recerca de la Catalunya Central, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Sant Fruitós de Bages, Spain.
  • Zwaginga JJ; Salut Catalunya Central, Hospital de Berga, Berga, Spain.
  • Mitjà O; Salut Catalunya Central, Hospital de Berga, Berga, Spain.
  • Rijnders BJA; Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Nat Commun ; 13(1): 2583, 2022 05 11.
Article in English | MEDLINE | ID: covidwho-2252361
ABSTRACT
Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when <20% of recruitment target was achieved. A Bayesian-adaptive individual patient data meta-analysis was implemented. Outpatients aged ≥50 years and symptomatic for ≤7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with ≤5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution. TRIAL REGISTRATION Clinicaltrials.gov NCT04621123 and NCT04589949. REGISTRATION NCT04621123 and NCT04589949 on https//www. CLINICALTRIALS gov.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans / Middle aged Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-29911-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans / Middle aged Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-29911-3